N/A N=13 Randomized Supportive Care

Reward-Based Recovery Outcomes Management for Opioid Use Disorder

Opioid Use Disorder

Bottom Line

View on ClinicalTrials.gov: NCT04669249 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2023

Primary outcome: Primary: Percentage of Participants Fully-Adherent to Buprenorphine — 6; 3 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: PROCare (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Medical Decision Logic, Inc.
Primary completion: Sep 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage of Participants Fully-Adherent to Buprenorphine	6; 3	—
PRIMARY Percentage of Participants Fully-Adherent to Care Plan	4; 2; 6; 3	—
PRIMARY Percentage of Participants Completing Outcomes Monitoring Surveys	7; 4	—
SECONDARY Percentage of Participants Using Opioids	1; 1	—
SECONDARY Percentage of Participants Using Other Substances (Non-opioids)	2; 2	—
SECONDARY Change in Quality of Life as Assessed by EUROHIS-QOL 8-item Index From Baseline to 4-Week Follow-up	4.57; 1.50	—
SECONDARY Change in Opioid Craving as Assessed by Opioid Craving Scale (OCS) From Baseline to 4-Week Follow-up	19.42; 16.50	—
SECONDARY Motivation as Assessed by Readiness Ruler	93.49; 89.31	—
SECONDARY Change in Self-Efficacy as Assessed by Brief Situational Confidence Questionnaire (BSCQ) From Baseline to 4-Week Follow-up	54.62; 38.44	—
SECONDARY Change in Opioid Use Disorder Impairment From Baseline to 4-Week Follow-up	9.86; 7.50	—

Summary

A randomized pilot study assessing feasibility, acceptability, and preliminary effectiveness of a reward-based recovery management platform (PROCare) designed to enhance participation in outcomes monitoring, engagement in treatment care, and adherence to medication for opioid use disorder.

Eligibility Criteria

Inclusion Criteria

18 years of age or older
access to internet-enabled smartphone device
primary DSM-5 opioid use disorder diagnosis
receiving medication treatment for opioid use disorder with buprenorphine
English language proficient

Exclusion Criteria

active suicidal ideation or psychotic symptoms

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04669249). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.